CLS B Stock Overview
Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Clinical Laserthermia Systems AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr18.33 |
| 52 Week High | kr246.00 |
| 52 Week Low | kr14.40 |
| Beta | 0.48 |
| 1 Month Change | 20.91% |
| 3 Month Change | -23.63% |
| 1 Year Change | -91.10% |
| 3 Year Change | -97.60% |
| 5 Year Change | -99.07% |
| Change since IPO | -98.72% |
Recent News & Updates
Shareholder Returns
| CLS B | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 5.3% | 2.9% | 0.9% |
| 1Y | -91.1% | -7.5% | 10.3% |
Return vs Industry: CLS B underperformed the Swedish Medical Equipment industry which returned -7.5% over the past year.
Return vs Market: CLS B underperformed the Swedish Market which returned 10.3% over the past year.
Price Volatility
| CLS B volatility | |
|---|---|
| CLS B Average Weekly Movement | 12.2% |
| Medical Equipment Industry Average Movement | 7.1% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: CLS B's share price has been volatile over the past 3 months.
Volatility Over Time: CLS B's weekly volatility has decreased from 18% to 12% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 14 | Dan Mogren | www.clinicallaser.se |
Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment.
Clinical Laserthermia Systems AB (publ) Fundamentals Summary
| CLS B fundamental statistics | |
|---|---|
| Market cap | kr28.78b |
| Earnings (TTM) | -kr79.79m |
| Revenue (TTM) | kr8.27m |
3,479x
P/S Ratio-360.7x
P/E RatioIs CLS B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLS B income statement (TTM) | |
|---|---|
| Revenue | kr8.27m |
| Cost of Revenue | kr5.28m |
| Gross Profit | kr3.00m |
| Other Expenses | kr82.79m |
| Earnings | -kr79.79m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 17, 2024
| Earnings per share (EPS) | -0.051 |
| Gross Margin | 36.23% |
| Net Profit Margin | -964.49% |
| Debt/Equity Ratio | 0% |
How did CLS B perform over the long term?
See historical performance and comparison